[1] [1] GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Gas-troenterol Hepatol, 2022, 7: 796-829.

[2] [2] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136, E359-E386.

[3] [3] OZAKYOL A. Global epidemiology of hepatocellular carcinoma (HCC Epidemiology)[J]. J Gastrointest Cancer, 2017, 48 (3): 238-240.

[4] [4] EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67: 370-398.

[6] [6] SALAMA I I, SAMI S M, SALAMA S I, et al. Current and novel modalities for management of chronic hepatitis B infection[J]. World J Hepatol, 2023, 15(5): 585-608.

[8] [8] LEE I C, YANG S S, LEE C J, et al. Incidence and predictors of HBsAg loss after peginterferon therapy in HBeAg-negative chronic hepatitis B: a multicenter, long-term follow-up study[J]. J Infect Dis, 2018, 218(7): 1075-1084.

[9] [9] PFEFFERKORN M, SCHOTT T, BHM S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2021, 74(2): 283-292.

[11] [11] ZHANG X, LIN S M, YE F, et a1. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients[J]. J Viral Hepat, 2011, 18(7): e184-190.

[12] [12] FRIED M W, PIRATVISUTH T, LAU G K, et a1. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology, 2008, 47(2): 428-434.

[14] [14] WANG L, CAO X, WANG Z, et al. Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients[J]. J Clin Microbiol, 2019, 57(1): e01303-e01318.

[15] [15] KIMURA T, ROKUHARA A, SAKAMOTO Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load[J]. J Clin Microbiol, 2002, 40(2): 439-445.

[16] [16] ROKUHARA A, TANAKA E, MATSUMOTO A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen: a marker distinct from viral DNA for monitoring lamivudine treatment[J]. J Viral Hepat, 2003, 10 (4): 324-330.

[17] [17] KIMURA T, OHNO N, TERADA N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain[J]. J Biol Chem, 2005, 280(23): 21713-21719.

[18] [18] TESTONI B, LEBOSSE F, SCHOLTES C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4): 615-625.

[19] [19] ERKEN R, ZAAIJER H L, WILLEMSE S B, et al. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy[J]. Ann Hepatol, 2021, 26: 100540.

[20] [20] CHUAYPEN N, POSUWAN N, PAYUNGPORN S, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B[J]. Liver Int, 2016, 36(6): 827-836.

[21] [21] MARTINOT-PEIGNOUX M, LAPALUS M, MAYLIN S, et al. Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients[J]. J Viral Hepat, 2016, 23(11): 905-911.

[22] [22] HSU Y C, NGUYEN M H, MO L R, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk[J]. Aliment Pharmacol Ther, 2019, 49(1): 107-115.

[23] [23] HUANG D, WU D, WANG P, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB[J]. J Hepatol, 2022, 77(1): 42-54.

[24] [24] LI H, LIN X, LIU L, et al. Low level of serum immunoglobulin G is beneficial to clinical cure obtained with pegylated interferon therapy in inactive surface antigen carriers[J]. Front Immunol, 2022, 13: 864354.

[25] [25] SU X, CHEN H, ZHU Z, et al. Clinical diagnostic value of quantitative hepatitis B virus core antibody test in chronic viral hepatitis B[J]. Bioinorg Chem Appl, 2021, 2021: 3720571.

[26] [26] WANG W X, JIA R, GAO Y Y, et al. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG IFN in NA-suppressed chronic hepatitis B patients[J]. Front Immunol, 2022, 13: 894410.

[27] [27] MEIER M A, CALABRESE D, SUSLOV A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load[J]. J Hepatol, 2021, 75: 840-847.

[28] [28] GAN W, GAO N, GU L, et al. Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure[J]. J Clin Transl Hepatol, 2023, 11(2): 314-322.

[29] [29] ERKEN R, LOUKACHOV V, van DORT K, et al. Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B[J]. Hepatology, 2022, 76(1): 196-206.

[30] [30] TESTONI B, SCHOLTS C, PLISSONNIER M L, et al. Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B[J]. Gut, 2024, 73(4): 659-667.

[31] [31] WANG X, CHI X, WU R, et al. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment[J]. Virol J, 2021, 18(1): 4.

[32] [32] ZHANG M, LI G, SHANG J, et al. Rapidly decreased HBV RNApredicts responses of pegylated interferons in HBeAg-positive patients: alongitudinal cohort study[J]. Hepatol Int, 2020, 14(2): 212-224.

[33] [33] LI M H, ZHANG L, QU X J, et al. The predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon alpha-2a treatment[J]. Biomed Environ Sci, 2017, 30(3): 177-184.

[34] [34] FLINK H J, SPRENGERS D, HANSEN B E, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon{alpha}-2b therapy[J]. Gut, 2005, 54(11): 1604-1609.

[35] [35] CHOI H S J, SONNEVELD M J, FARAG M S, et al. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection[J]. J Viral Hepat, 2021, 28(12): 1729-1737.

[36] [36] PERRILLO R, LOK A S, LEONARD K, et al. Association of alanine aminotransferase flares to hepatitis B surface decline during tenofovir alone or with pegylated interferon alfa[J]. Am J Gastroenterol, 2023, 118(11): 2075-2079.

[37] [37] YUAN W, HUANG D, WU D, et al. Peg IFN-a treatment enhanced the inhibitory effect of NK cells on the differentiation and proliferation of CD4+CD25+ tregs via IFN-gamma in chronic hepatitis B[J]. J Infect Dis, 2021, 224(11): 1878-1889.

[38] [38] PANG X, ZHANG L, LIU N, et al. Combination of pegylatedinterferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients[J]. Clin Exp Immunol, 2020, 200(1): 100-110.

[39] [39] CAO W, LI M, ZHANG L, et al. The characteristics of natural killer cells in chronic hepatitis B patients who received PEGylated-interferon versus entecavir therapy[J]. Biomed Res Int, 2021, 2021: 100-110.

[40] [40] CAO W, LU H, ZHANG L, et al. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN alpha-2a therapy[J]. Front Immunol, 2022, 13: 1067362.

[41] [41] CAO W, XIE S, ZHANG L, et al. Expression of functional molecule on plasmacytoid dendritic cells is associated with HBsAg loss in HBeAg-positive patients during PEG-IFN -2a treatment[J]. Front Immunol, 2022, 13: 891424.

[42] [42] TIAN C, CHEN Y, LIU Y, et al. Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans[J]. Emerg Microbes Infect, 2018(7): 16.

[43] [43] WU Z Q, TAN L, GAN W Q, et al. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-alpha[J]. Ann Transl Med, 2021, 9(5): 414.

[45] [45] LAU S K, CHU P G, WEISS L M. CD163: a specific marker of macrophages in paraffin-embedded tissue samples[J]. Am J Clin Pathol, 2004, 122(5): 794-801.

[46] [46] XIE P, YAO B, HUANG D, et al. Soluble CD163 and CD163 expression on monocytes associated with chronic hepatitis B inflammation and HBsAg loss[J]. J Clin Transl Hepatol, 2022, 10(6): 1059-1067.

[47] [47] ZHANG Y, HAN J, ZHANG X, et al. Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon[J]. Liver Int, 2022, 43(2): 329-339.

[48] [48] LEE I C, HUANG Y H, SU C W, et al. CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: apilot study[J]. PLoS One, 2013, 8(10): e76798.

[49] [49] LI H, LIN X, LIU L, et al. Low level of serum immunoglobulin G is beneficial to clinical cure obtained with pegylated interferon therapy in inactive surface antigen carriers[J]. Front Immunol, 2022, 13: 864354.

[50] [50] CHEN J, WANG X M, WU X J, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B[J]. Inflamm Res, 2011, 60(1): 47-53.

[51] [51] ZHU L, LI J, XU J, et al. Significance of T-cell subsets for clinical response to peginterferon Alfa-2a therapy in HBeAg-positive chronic hepatitis B patients[J]. Int J Gen Med, 2022, 15: 4441-4451.

[52] [52] LIU Y, HU X, HU X, et al. T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production[J]. J Gastroenterol, 2022, 57 (1): 30-45.

[53] [53] KAWAI T, AKIRA S. Regulation of innate immune signalling pathways by the tripartite motif (TRIM) family proteins[J]. EMBO Mol Med, 2011, 3(9): 513-527.

[54] [54] UCHIL P D, HINZ A, SIEGEL S, et al. TRIM. protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity[J]. J Virol, 2013, 87(1): 257-272.

[55] [55] LUO H, TAN G, HU X, et al. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during PEG IFN therapy[J]. Virol J, 2023, 20(1): 161.

[56] [56] BADARY T M, ELBADAWY O, AGBAN M N, et al. Evaluation of serum IFN-g and IL-5 levels in response to entecavir therapy in patients with chronic hepatitis b virus infection[J]. Egypt J Immunol, 2018, 25(1): 93-103.

[57] [57] WANG P, MO Z, ZHANG Y, et al. Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon[J]. Front Immunol, 2023, 13: 1104329.

[58] [58] LUO M, HOU J, MAI H, et al. TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFN treatment response of HBeAg-positive chronic hepatitis B Patients[J]. Aliment Pharmacol Ther, 2022, 56(5): 878-889.

[59] [59] CHEN J X, CHEN H T, JIANG D K, et al. Exploring the role of a CD40 functional variant in HBV clearance reveal a novel predictor of PegIFN treatment response[C]//AASLD 2022, 2022: 1124.